



Corporate Fact Sheet

Overview Founded in Geneva, Switzerland in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact-force measurement in catheter ablation with the development of its TactiCath® catheter. The TactiCath is the first force-sensing ablation catheter to give physicians a real-time, objective measure of tip-to-tissue contact force during the catheter ablation procedure.

Market Focus Endosense's therapeutic focus is the catheter ablation treatment of cardiac rhythm disorders. Atrial fibrillation (AF) is the most common cardiac rhythm disorder today, affecting more than six million people worldwide. Most AF patients are currently treated with ineffective and side effect-causing pharmaceutical drugs, with the primary alternative invasive ablation surgery. This sizeable patient population represents a multi-billion dollar market opportunity for Endosense and its groundbreaking catheter ablation technology.

Clinical Milestones Endosense has built an extensive foundation of scientific evidence supporting the value of force sensing in improving patient outcomes of catheter ablation procedures. The company's TactiCath ablation catheter and accompanying TactiSys® system have undergone extensive pre-clinical and clinical validation in the United States and Europe, with study results appearing in more than 30 clinical presentations or peer-reviewed publications since 2003. Endosense is currently conducting a range of post-market studies as well as an Investigational Device Exemption (IDE) clinical trial. These include the following.

EFFICAS

Launched in May 2010, EFFICAS is a series of European post-market studies that intended to demonstrate that the use of contact-force control during cardiac ablation utilizing the TactiCath force-sensing catheter results in superior outcomes as compared to ablations performed without a force sensor. EFFICAS I investigators used the TactiCath but were blinded to contact-force measurements during the procedures. Early results of EFFICAS I, which were presented at Heart Rhythm 2011, indicated a predictive relationship between low contact force and early pulmonary vein isolation (PVI) line reconnection. EFFICAS II, in which investigators may use contact-force data to improve their ablation technique, launched in December 2010.

ProForce Registry Study

Launched in June 2010, the ProForce Registry Study is an international, single arm, multi-center, post-market trial of up to 2,000 patients that will evaluate the use and impact of contact-force monitoring during catheter ablation procedures.

TOCCASTAR

Launched in January 2011 and currently actively enrolling patients, TOCCASTAR is a prospective, randomized, multi-center Investigational Device Exemption (IDE) study of the TactiCath's effectiveness and safety. The results of TOCCASTAR will

be used in the submission of a Premarket Approval (PMA) application for market clearance by the U.S. Food and Drug Administration.

**Commercial
Milestones**

The TactiCath and TactiSys were granted CE mark in October 2009 for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). The second generation of the novel device, which launched in April 2010 with a full release in September 2010, has been used since then to treat more than one thousand patients across Europe. Endosense's exclusive product distributor in Europe, Latin America, Canada, Africa and the Middle East is BIOTRONIK. Endosense intends to greatly expand access to contact-force sensing in the electrophysiology lab with an open platform strategy to integrate its technology into a range of three-dimensional mapping systems. Current joint development partners include Siemens Healthcare, GE Healthcare and Rhythmia Medical.

Financing

Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

**Management
Team**

Jan Keltjen, President and Chief Executive Officer
Giovanni Leo, Co-founder and Chief Technology Officer
Andrea Buscaglia, Chief Financial Officer
Laurent Grandidier, Vice President, Sales and Marketing
Hendrik Lambert, Ph.D., Vice President Quality Assurance, Clinical and Regulatory Affairs
David Enfrun, Manufacturing Director

**Scientific
Advisors**

Warren Jackman, M.D., University of Oklahoma
Karl-Heinz Kuck, M.D., St. Georg Hospital, Hamburg
Hiroshi Nakagawa, M.D., Ph.D., University of Oklahoma
Andrea Natale, M.D., Texas Cardiac Arrhythmias Institute, Austin
Vivek Reddy, M.D., Mount Sinai Medical Center, New York
Nadir Saoudi, M.D., Ph.D., Princess Grace Hospital, Monaco
Dipen Shah, M.D., University Hospital of Geneva

**Contact
Information**

Endosense
Chemin du Grand-Puits 42
1217 Meyrin – Geneva, Switzerland
Phone: + 41 22 306 19 60
www.endosense.com

¹CAUTION: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.

Laura Nobles
Nobles Communications
+1 310-795-0497
laura@noblescommunications.com

Danièle Castle
Genevensis Communications
+41 79 202 6667
info@genevensis.com

###